Haughey B H, Gates G A, Arfken C L, Harvey J
Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO 63108.
Ann Otol Rhinol Laryngol. 1992 Feb;101(2 Pt 1):105-12. doi: 10.1177/000348949210100201.
A meta-analysis was performed on data from the Washington University Department of Otolaryngology Head and Neck Tumor Registry and 24 studies reporting synchronous and metachronous malignancies in head and neck cancer patients. The overall second malignant tumor (second primary) prevalence was 14.2% in 40,287 patients, the majority of tumors being metachronous. Site relationships between index tumors and second primaries revealed significantly high risks along the digestive tract axis or the respiratory tract axis, although lung second primaries were prevalent in all groups. Head and neck second primaries were the largest group, being significantly more common in the oral cavity, oropharynx, and hypopharynx than in the larynx. Oral cavity index tumors showed the highest overall rate of second primary formation. Half of all aerodigestive tract second primaries are detected by 2 years from index tumor presentation, but non-aerodigestive tract tumors are common beyond 5 years. A significantly higher detection rate was proven for the prospective panendoscopy studies. We recommend routine interval endoscopic intervention within 2 years of treatment for optimum detection of second primaries in head and neck cancer patients. Also, a lifetime of clinical surveillance is suggested for aerodigestive tract second neoplasms in oral cavity, oropharynx, and hypopharynx cancer patients and for lung and non-aerodigestive tract neoplasms in larynx cancer patients.
对来自华盛顿大学耳鼻咽喉头颈肿瘤登记处的数据以及24项报告头颈癌患者同步和异时性恶性肿瘤的研究进行了荟萃分析。在40287例患者中,总体第二原发恶性肿瘤(第二原发癌)患病率为14.2%,大多数肿瘤为异时性。原发肿瘤与第二原发癌之间的部位关系显示,沿消化道轴或呼吸道轴存在显著高风险,尽管在所有组中肺癌第二原发癌都很常见。头颈第二原发癌是最大的一组,在口腔、口咽和下咽比在喉更常见。口腔原发肿瘤显示出第二原发癌形成的总体发生率最高。所有上消化道和呼吸道第二原发癌中有一半在原发肿瘤出现后2年内被检测到,但非上消化道和呼吸道肿瘤在5年后很常见。前瞻性全内镜检查研究的检测率明显更高。我们建议在头颈癌患者治疗后2年内进行常规间隔内镜干预,以实现对第二原发癌的最佳检测。此外,建议对口腔、口咽和下咽癌患者的上消化道和呼吸道第二肿瘤以及喉癌患者的肺癌和非上消化道和呼吸道肿瘤进行终身临床监测。